Cic edizioni internazionali
Clinical Dermatology

Topical rapamycin in facial angiofibromas: patients satisfaction versus objective response, and a literature review

Original Article, 93 - 98
doi: 10.11138/cderm/2014.2.2.093
Tag this article
Abstract
Enhanced HTML Full text PDF
Facial Angiofibromas (FA) are a common cutaneous manifestation of Tuberous Sclerosis (TS).
Different therapies have been employed until now (surgery, CO2 laser…) without successful and permanent effects. Recently, topical rapamycin has been reported as a new and effective treatment without significant adverse effects.
We present our experience in four adult patients with FA and TS who have been treated with 1% rapamycin ointment for three months. We evaluated the objective response achieved by using the Facial
Angiofibromas Severity Index (FASI). On the other hand, in order to know the patients’ subjective satisfaction they completed a questionnaire to evaluate this therapy.
We noticed a slight reduction of erythema, size and number of FA, lower than published in the literature.
Despite this, overall satisfaction was high or very high even if the FA reappeared months after discontinuing the application.
We wonder if this subjective response justifies the costs of this treatment nowadays, especially in adult patients in which the established fibrosis in the FA could decrease the efficacy of the ointment. We also present a review of all published cases to date.

Vol. 5 (No. 1) 2017 January - March

  1. Unmet needs in hidradenitis suppurativa: patients’ perspective on daily management and cosmetic cares
    Atzori L., Pintori G., Patta F., Pinn A.L., Rongioletti F.
    doi: 10.11138/cderm/2017.5.1.001
  2. EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro
    Umbert I., Sans G., Valls J., Márquez L., Costales P., Fernández L.
    doi: 10.11138/cderm/2017.5.1.005
  3. Cutaneous leishmaniasis and its clinical spectrum. An overview from the Old World
    Dassoni F.
    doi: 10.11138/cderm/2017.5.1.012
  4. Systemic immunosuppressive treatment in adult patients with atopic dermatitis: current and new treatment options
    van der Schaft J., Thijs J.L., Hijnen D., de Bruin-Weller M.S.
    doi: 10.11138/cderm/2017.5.1.022
  5. Possible role of mast cells and IL-37 in the pathogenesis of psoriasis
    Conti P., Caraffa A., Spinas E., Lessiani G., Kritas S.K., Ronconi G., Theoharides T.C.
    doi: 10.11138/cderm/2017.5.1.030
  6. Commentary on dermoscopy in general dermatology
    Russo T., Piccolo V., Agozzino M., Moscarella E., Lallas A., Argenziano G.
    doi: 10.11138/cderm/2017.5.1.037
  7. Gluten related disorders: even a dermatological issue
    Bonciolini V., Caproni M.
    doi: 10.11138/cderm/2017.5.1.043
  8. Congenital mastocytosis
    Virdi A., Neri I., Gurioli C., Patrizi A.
    doi: 10.11138/cderm/2017.5.1.048
  9. Frontal fibrosing alopecia: when the treatment is worse than the disease
    Lai M., Brundu M.A., Atzori L.
    doi: 10.11138/cderm/2017.5.1.060
Last Viewed articles: la lista degli ultimi x visitati.
  1. Topical rapamycin in facial angiofibromas: patients satisfaction versus objective response, and a literature review
    Rodrigo-Nicolás B., Armengot-Carbó M., Molés-Poveda P., Millán-Parrilla F., Pont-Sanjuán V., Quecedo-Estébanez E., Soriano-Clemente A., Gimeno-Carpio E.
    doi: 10.11138/cderm/2014.2.2.093
credits